UNSPSC 51171828: Azasetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H20ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77HC7URR9Z, chemically known as 2h-1,4-benzoxazine-8-carboxamide, n-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride but generally known as azasetron, which bears US NIH Compound Identifier 2264. Azasetron most often comes in base and hydrochloride forms.

UNSPSC 51171828 Azasetron is a Commodity code covering pharmaceutical products. State and local governments procure azasetron primarily through cooperative purchasing vehicles and consolidated multi-vendor pharmaceutical agreements rather than direct individual solicitations. Recent activity shows that azasetron procurement operates within broader frameworks: the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products establishes master contracts with manufacturers that authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) then distribute to state and local health facilities. Pricing is evaluated on competitiveness (weighted at 75 percent in MMCAP's scoring), with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with at least two of three authorized wholesalers. Beyond cooperative purchasing, state and local health and human services agencies also procure azasetron as part of broader pharmaceutical benefit management initiatives — the Texas Health and Human Services Commission recently issued an RFI exploring direct-to-manufacturer prescription programs that could reshape how state agencies source individual drugs.

Geographic activity centers on the Upper Midwest and Texas. The MMCAP cooperative, administered by the Minnesota Department of Administration with participation extending to Oregon and other member jurisdictions, represents the most active recent procurement vehicle under this code, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Texas HHS issued its TPI Direct-to-Manufacturer RFI in April 2026 as exploratory research, signaling potential future demand. Collin County Community Supervision and Corrections Department's July 2026 RFP for offender drug testing services demonstrates localized procurement of pharmaceutical screening and confirmation services rather than azasetron specifically, indicating that some state-local tagging may reflect testing methodologies (immunoassay, LC/MS/MS, GC/MS) rather than active ingredient procurement. The cooperative purchasing model dominates — MMCAP contracts run through June 2028 with optional extensions, and manufacturers must commit to pricing flexibility via multiple net-price formats and WAC-minus structures, with administrative fees of 3 percent levied on all purchases.